Production (Stage)
Cartesian Therapeutics, Inc.
RNAC
$10.46
$0.1351.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 84.97% | 64.76% | -16,364.63% | -- | -- |
| Total Depreciation and Amortization | 159.02% | 36.54% | -47.06% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -94.17% | -64.12% | 5,708.80% | -- | -- |
| Change in Net Operating Assets | 7.09% | -216.50% | 69.36% | -- | -- |
| Cash from Operations | 47.07% | 53.73% | 30.69% | -- | -- |
| Capital Expenditure | -1,310.91% | -4,314.08% | -609.06% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | -- | -- |
| Cash from Investing | -256.64% | -125.26% | -114.26% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | 3,936.17% | 55,525.11% | 222.69% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | 97.53% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -34.12% | 98.93% | -5,508.18% | -- | -- |
| Cash from Financing | 294.70% | 1,381.31% | 1,415.77% | -- | -- |
| Foreign Exchange rate Adjustments | 143.24% | 60.38% | 120.41% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 440.11% | 557.11% | 531.10% | -- | -- |